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Abstract
We analyzed late cardiovascular outcomes of 661 patients who survived at least two years from 
hematopoietic cell transplantation for childhood hematologic malignancy between 1995 and 2008. 
Center for International Blood and Marrow Transplant Research data was supplemented with 
surveys focused on cardiotoxicity and potential risk factors. The median duration of follow-up was 
97 months (range 24–230). 4.2% of survivors experienced at least one of the primary outcomes 
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including coronary artery disease (0.2%), cerebrovascular accident (0.6%), cardiomyopathy (3%), 
and cardiac-related death (0.5%). Patients who received anthracycline chemotherapy (HR 4.67, p= 
0.036) or cranial or chest radiation (HR 5.58, p<0.0001; HR 2.18, p= 0.0087) were at increased 
risk for developing one of the primary outcomes. Dyslipidemia was diagnosed in 18% of 
survivors. Pre-transplant anthracycline (HR 1.74, p< 0.0001) and chest radiation (HR 1.34, p= 
0.0371) were risk factors for dyslipidemia. Overweight/obese body mass status was present in 
63% of patients at baseline, 65% at 2 years, and 52% at most recent evaluation. Diabetes was 
diagnosed in 7% of subjects. In conclusion, severe cardiovascular complications were infrequently 
reported. The incidence of risk factors including obesity and dyslipidemia were significant and 
will likely increase the risk of cardiovascular disease over time in transplant survivors.
Introduction
Survivors of allogeneic hematopoietic cell transplantation (HCT) are at risk for 
cardiovascular (CV) late effects including early cardiac death.1–3 Contributing to this risk 
are genetic predisposition, pretransplant therapeutic exposures, the transplant conditioning 
regimen, graft-versus-host disease (GVHD) and associated-therapies, post-transplant 
complications, and life style factors.4–8 The majority of the literature regarding late CV 
complications of childhood leukemia therapy comes from the study of non-transplant 
survivors.7, 9–11 Far less is known about these late effects following HCT in childhood.
This multicenter study sought to establish the incidence of severe CV related adverse 
outcomes in a cohort of long-term survivors of childhood transplantation. We examined the 
incidence of risk factors associated with CV disease and how they, along with patient and 
treatment related factors, influenced the development of CV adverse outcomes.
Materials and Methods
Study Population
The study population included patients aged 21 years or less at the time of transplant who 
survived, relapse-free at least two years following first allogeneic HCT for hematologic 
malignancy between January 1, 1995 and December 31, 2008. Transplants were performed 
at twelve Pediatric Blood and Marrow Transplantation Consortium (PBMTC) centers. All 
patients received a myeloablative conditioning regimen based on the definition published by 
Bacigalupo, et al.12 All stem cell sources and donor types were included except syngeneic 
twins. Patients who developed one of the primary CV outcomes of interest within the first 
two years following transplant were excluded from the analysis to distinguish acute toxicity 
from late effects.
Data Collection
Data were obtained from the Center for International Blood and Marrow Transplant 
Research (CIBMTR) database and from pre- and post-HCT supplemental forms. The 
CIBMTR has a research database with information on more than 425,000 patients. 
Computerized checks for discrepancies, physicians’ review of submitted data and center 
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audits ensure data quality. Data are collected before transplant, 100 days and six months 
after transplant, annually until 6 years, and every other year thereafter, or until death.
Data regarding patient demographics, disease, survival, relapse, graft type, and the presence 
of GVHD is collected for all patients participating in the CIBMTR repository. A subset of 
participants are selected for research level data collection including all patients in this study. 
Centers report the presence of clinically significant organ impairment including the presence 
of CV and related late effects.
Data not available in the CIBMTR database were collected on forms focused on pre- and 
post-transplant exposures. Data obtained from the pre-transplant form included the use of 
anthracycline chemotherapy in isotoxic doxorubicin equivalents, the use of cranial and/or 
chest radiation, history of medication treated hypertension, lipid abnormalities, clinically 
significant cardiomyopathy, coronary artery disease (CAD)/MI, stroke/cerebrovascular 
accident (CVA), the presence of diabetes treated with medications, and the presence of 
cardiac structural defect(s). Data from the post-transplant form included the prescription of 
medications used to treat hypertension, diabetes, or lipid abnormalities; dyslipidemia; the 
development of new cardiomyopathy, CAD/MI, stroke/CVA; and height and weight at 2 
years post-transplant and at most recent follow-up.
Primary Cardiovascular Outcomes—The primary aim of this study was to establish 
the cumulative incidence of CV outcomes (CAD/MI, stroke/CVA, cardiomyopathy, and 
cardiac-related death) in patients who survived disease-free a minimum of two years 
following allogeneic transplant. CAD/MI or stroke/CVA were recorded if any of the 
diagnoses were reported by a physician two years or longer after transplant. Clinically 
significant cardiomyopathy was defined as the presence of decreased ejection or shortening 
fraction that was determined to be clinically significant by the attending transplant physician 
and required ongoing treatment or follow-up. There was no specific ejection or shortening 
fraction required for the diagnosis of cardiomyopathy. It was not determined if the diagnosis 
was based on routine clinical screening or clinical symptom. Cardiac-related death was 
reported if the primary cause of death reported was cardiovascular in nature. All reports of 
cardiac-related deaths were reviewed by two study physicians.
Cardiovascular Risk Factors
We examined the incidence of risk factors associated with CV disease including obesity 
based on body mass index (BMI), diabetes, hypertension, and dyslipidemia. We additionally 
investigated patient (age, diagnosis, gender, and race) and treatment related factors (pre-
HCT therapy, conditioning regimen, and GVHD) and their effect on CV outcomes.
The BMI was calculated prior to the start of transplant conditioning, 2 years post-HCT, and 
at most recent follow-up. Normative BMI values are not defined for children less than 2 
years old and patients in this age group were excluded from the baseline assessment. BMI 
status was classified as underweight, normal weight, obese, and overweight based on 
Centers for Disease Control and Prevention (CDC) definitions.13, 14 For survivors aged 2 to 
20 years, BMI was characterized by calculating an age and sex specific percentile according 
the 2000 CDC Growth Charts.15 In this age group BMI status below 5th percentile was 
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classified as underweight, 5%–84.9% normal weight, 85%–94.9% overweight, and 95% and 
above as obese. For patients older than 20 years a BMI less than 18.5 was classified as 
underweight, 18.5–24.9 as normal weight, 25–29.9 as overweight, and 30 and greater as 
obese.
Dyslipidemia was defined as a triglyceride level >150 mg/dl, high-density lipoprotein 
(HDL) cholesterol level <40 mg/dl, and/or low-density lipoprotein (LDL) cholesterol level 
>130 mg/dl. A subject was classified as having diabetes if the diagnosis was documented in 
the patient’s medical record and he/she received insulin or oral hypoglycemic medication 
two years or later after transplant. Hypertension was defined as having elevated blood 
pressure that was treated with medication.
Statistical Analysis
Descriptive statistics were used to summarize patient demographic, disease, HCT-related 
variables, dyslipidemia, and BMI status. The cumulative incidence function was used to 
estimate the probability of experiencing a primary CV outcome. No adjustments were made 
for age at follow-up. Univariate models were developed to assess risk factors for the primary 
CV outcomes, dyslipidemia, and obesity. Death and relapse were treated as competing risks. 
Multivariable regression models were not developed due to sample size limitations. All tests 
were two-sided and 5% level of significance was used throughout. The same data points 
were not routinely collected over the entire length of the study at all centers and clinical 
standards of care evolved over time resulting in missing data. When data were missing, 
patients were excluded from those analyses affected by the missing data, but included in all 
other analyses. Analyses were performed using SAS, version 9.3 (SAS Institute, Cary, NC).
Results
Study Population and Transplant Characteristics
The final study population included 661 patients. The selection schema is provided in Figure 
1. Patient and transplant characteristics are presented in Table 1. The median age at 
transplantation was 9 years (range <1–21years). The median duration of follow-up was 8 
years (range 2–19 years) from transplantation. The CIBMTR completeness index of follow-
up, the ratio of observed versus expected data follow-up, was 96% at 5 years and 86% at 10 
years, meaning that forms were complete for 96% of patients at 5 years following transplant. 
Pre-transplant treatment and CV characteristics are provided in Table 2.
Primary Cardiac Outcomes
There were 30 diagnoses of one of the primary cardiac outcomes in 28 patients including 
cardiomyopathy (3%), stroke/CVA (0.6%), cardiac-related death (0.5%), and CAD/MI 
(0.2%) (Table 3). The cumulative incidence of the primary outcomes was 1% (95% 
confidence interval, CI, 1–2%) at 5-years and 3% (95% CI 2–4%) at 7-years post-transplant. 
Pre-transplant anthracycline chemotherapy (HR 4.67, p= 0.0361), cranial radiation (HR 
5.58, p= <0.0001), and chest radiation (HR 2.86, p= 0.0087) were associated with the 
development of one or more of the primary outcomes. Patients who received both chest and 
cranial radiation were at greatest risk for developing one of the primary outcomes compared 
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to those who received neither treatment (HR 12.97, p <0.001). The doses of anthracycline or 
radiation were not significantly predictive of the development of one of the primary 
outcomes Age at transplant, sex, underlying disease, race, donor type, graft source, 
conditioning regimen, the use of TBI, the diagnosis of GVHD, the diagnosis of 
dyslipidemia, and BMI were not predictive of the development of one of the primary 
cardiovascular outcomes. There were 39 patients who had pre-transplant cardiac structural 
defect, coronary artery disease/myocardial infarction, and/or cardiomyopathy. Of those 39 
patients, only 1 (2.5%) developed the primary outcome following transplant.
Dyslipidemia, Diabetes, and Hypertension
The cumulative incidence of dyslipidemia diagnosed at any time after transplant was 56% 
(95% CI 52–60) and 63% (95% CI 59–67) at 2 years and 5 years post-HCT. The details of 
cholesterol and triglyceride abnormalities are provided in Table 3. In single predictor, 
univariable analysis patients who received pre-transplant anthracycline chemotherapy (HR 
1.74, p<0.001) or chest radiation (1.34, p=0.0371) were more likely to be diagnosed with 
dyslipidemia than those who did not receive those therapies. The risk of dyslipidemia 
increased 1% for every 10 mg/m2 increase in the cumulative dose of anthracycline received 
(p=0.0313). Increased doses of radiation were not significantly associated with risk of 
dyslipidemia. Chronic GVHD was a risk factor for the development of dyslipidemia 
(HR=1.45, p=0.0277). Age, sex, underlying diagnosis, race, donor type, graft source, 
conditioning regimen, the use of TBI, and BMI were not predictive of the development of 
dyslipidemia. Pre-transplant triglyceride, HDL, and LDL levels were not available for 42%, 
77%, and 77% of patients. Therefore, a potential association between pre- and post-
transplant dyslipidemia could not be assessed.
Diabetes requiring medication was diagnosed in 7% of patients at any time following 
transplant. Half of the patients received anti-hypertensive medications at some point after 
HCT inclusive of the first two years after transplant with 9% still taking them at most recent 
follow-up.
Body Mass Index
The BMI status of the population at baseline, two years after transplant, and at most recent 
evaluation are presented in Table 4. There were more patients with obese status than any 
other category at each time point assessed. Age, pre-transplant therapy, sex, race, diagnosis, 
donor source, graft source, conditioning regimen, the use of TBI, presence of GVHD, and 
baseline BMI were not associated with obesity at 2 years from transplant.
Graft-versus-Host Disease and Survival
Grade II–IV acute GVHD was diagnosed in 45% of the population at any time post-HCT 
and chronic GVHD in 45% of patients; 11% diagnosed greater than 2 years from transplant. 
The overall and progression-free survival at 7 years of patients who were alive, disease-free 
at least 2 years post-transplant were 94% and 89%, respectively. The causes of death in the 
entire study population were GVHD (22 patients, 42%), relapse of primary disease (14 
patients, 27%), subsequent malignancy (7 patients, 13%), infection (3 patients, 6%), and 
other/unknown (6 patients, 12%). There were three cardiac-related deaths including 2 
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cardiac deaths in patients with chronic GVHD and one patient who died of anoxic brain 
injury following cardio-pulmonary arrest. The patients who died of cardiac related causes 
included a 14 year old female patient who received an unrelated donor peripheral blood stem 
cell transplant for AML, a 14 year old male patient who received a matched sibling bone 
marrow transplant for AML, and a 7 year old boy who received an unrelated donor, bone 
marrow transplant. The ages provided were those at transplantation. There were two other 
deaths in the patients who had one of the primary CV outcomes, one of relapse of the 
primary disease and the other of a subsequent malignancy.
Discussion
In this multicenter study, we investigated the long-term CV outcomes of 661 patients 
transplanted for hematologic malignancy during childhood. The largest previously published 
multicenter studies of late CV toxicity from groups in the United States and the European 
Group for Blood and Marrow Transplantation included less than 200 per report making this 
the largest report of these issues following HCT in childhood to date.16, 17
We report a cumulative incidence of cardiomyopathy, stroke/CVA, CAD/MI, and cardiac-
related death of 1% at 5 years and 3% at 7 years post-transplantation. This suggests that the 
incidence of CV late effects will increase as the cohort ages, consistent with data from 
survivors of non-transplant childhood leukemia therapy and adult HCT.1, 7, 18–20 Stroke/
CVA, CAD/MI, and cardiac-related death each occurred in less than 1% of survivors. The 
low incidence of these events may be explained by the duration of follow-up and the age of 
the patients at the time of reporting. Studies of survivors of adult transplantation have shown 
the development of CV outcomes at a younger than expected age and that greater toxicity is 
seen with longer duration of follow-up.3, 18, 21–23 Given the median age of 18.5 years at last 
follow-up, the survivors in this cohort are young for the development of CV late effects. We 
hypothesize that the incidence of CV toxicity will increase as the cohort ages and future 
study will be needed.
Cardiomyopathy was diagnosed in 3% of patients making it the most common of the 
primary late effects assessed. This may be explained by the number of patients who received 
anthracycline chemotherapy and/or radiation therapy prior to transplantation. Anthracycline 
chemotherapy use is a well-established, dose-dependent risk factor for cardiomyopathy in 
cancer survivors that is worsened by radiation exposure.10 The median cumulative dose of 
anthracycline received by patients in this cohort, 112 mg/m2, is below that associated with 
greatest risk of cardiotoxicity.10, 11, 24, 25 However, there was a wide range of cumulative 
dose received with the highest reported dose of 634 mg/m2 and increasing doses of 
anthracycline were predictive of the development of one of primary outcomes. Based on the 
small number of events we were unable to determine the additive impact of transplant-
specific factors on the development of cardiomyopathy in patients who received 
anthracycline chemotherapy.
We found that cranial radiation was associated with increased risk of developing one of the 
primary outcomes. The pathophysiologic mechanism underlying this risk is unclear. A 
potential explanation relates radiation-mediated hypothalamic-pituitary dysfunction leading 
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to growth hormone deficiency and decreased synthesis of insulin-like growth factor-1 
(IGF-1).26 Deficiency of growth hormone and/or IGF-1 have been linked to myocardial 
hypokinesis, altered cardiac growth, and abnormal response to exercise.26–29 A single center 
study compared the cardiac structure and function of 13 survivors of childhood cancer 
therapy who received cranial radiation therapy without systemic chemotherapy to their 
healthy siblings.26 They found that the childhood cancer survivors who received cranial 
radiation therapy had lower IGF-1 levels, smaller cardiac volumes and decreased left 
ventricular systolic and diastolic function compared to their siblings. A separate study of 
childhood cancer survivors reported that treatment with cranial radiation and anthracycline 
chemotherapy were associated with decreases in left ventricular mass and dimension greater 
than those who received anthracycline chemotherapy without radiation.30
We did not identify associations of transplant specific factors with the development of one of 
the primary cardiovascular outcomes. The only transplant-related factor associated with any 
study outcome was that of chronic GVHD with dyslipidemia. This result may have been 
confounded by the use of medications used to treat GVHD that can cause lipid abnormalities 
such as corticosteroid and sirolimus. The lack of association of TBI with the development of 
one of the primary CV outcomes, dyslipidemia, or obesity was unexpected and differs from 
prior reports that identified it as an independent risk factor for late CV toxicity.31, 32 A 
potential explanation is that survivors who received non-TBI based conditioning may have 
had additional factors that increased their risk for CV outcomes making it difficult to 
distinguish the impact of TBI. Another potential explanation is that the conditioning agents 
used instead of TBI may have late deleterious cardiovascular effects similar to those seen 
following radiation therapy.
Cholesterol abnormalities and dyslipidemia are risk factors for childhood CV illness that 
influence the development of disease in adulthood.33 Data from the 2011–2014 National 
Health and Nutrition Examination Surveys (NHANES) showed that 21% of children aged 6–
19 years had at least one abnormal cholesterol measure with low HDL and high non-HDL 
reported in 13.4% and 8.4% of those tested.34 The prevalence increased with BMI status and 
older age.34 We report low HDL and high LDL cholesterol measures in 15% and 10% of 
patients tested, comparable to those described in the NHANES of otherwise healthy 
children.35 The American Academy of Pediatrics (AAP) and expert panel recommendations 
advise universal lipid screening of all 9–11 year old children with additional screening of 
younger children and adolescents based on individual CV risk factors and family history.
36, 37
 Due to the large amount of missing cholesterol data we are unable provide data derived 
screening guidelines for transplant survivors. However, we suggest that at minimum patients 
should have the routine surveillance recommended by expert panel and the AAP.34, 36, 3735 
Furthermore, we advocate for heightened surveillance in survivors with additional risk 
factors including history of GVHD, obesity and older age. The large number of patients with 
missing lipid measurements in our study suggests that regular monitoring may not be 
performed at all transplant centers. If dyslipidemia screening is not routinely performed by 
the HCT center, then survivors should be counselled to have testing completed by another 
medical professional.
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Childhood obesity is a significant problem in the general population and pediatric cancer 
survivors. The negative impact of childhood obesity on factors associated with CV health is 
well-documented and may influence the development of hypertension, cholesterol 
abnormalities, diabetes, and insulin insensitivity in adulthood.38, 39 Reports of obese and 
overweight/obese status in the general population of 2–19 year old children are 16.9% and 
31.7%.40 There is a range of obesity estimates in adult survivors of childhood non-transplant 
leukemia therapy with reported rates of 16–43%.41–45 This study found rates of overweight/
obese BMI status of 63% and 52% of those with available data at baseline and most recent 
follow-up respectively, exceeding those reported in the general population and survivors of 
non-HCT childhood cancer therapy. However, 35% of patients had missing BMI data at 
baseline and it is possible that this affected the reported rates of overweight/obese status. 
The high rate of obese/overweight BMI status at baseline may have been in part due to 
recent pretransplant leukemia directed therapies, including corticosteroid. These results 
support routine assessment for and counseling about optimal weight and body mass in 
transplant survivors. Interventions to effectively decrease the risk of obesity are needed.
There are limitations to this study. There was lack of uniformity in clinical practice between 
centers and standards of care changed during the 13-year study window resulting in missing 
data that may have affected the reported outcomes with a bias likely in the direction of 
underreporting. Precise start dates for medications were not reliably recorded in the medical 
record, which made it impossible to determine the date of diagnosis for conditions such as 
diabetes that relied on medication use. In these cases, we were unable to discern acute 
toxicity from true late effect. Patients with diabetes/hyperglycemia and/or hypertension 
treated with nonpharmaceutical, lifestyle modification were not reported as having either 
late effect. It is possible that this lead to an underestimation of the true incidence of these 
long-term toxicities. Additionally, we were unable to assess potential predictive factors, such 
as genetics and lifestyle behaviors due to the retrospective nature of the study and we were 
unable to perform multivariate analysis due to the small number of primary events. We were 
unable to investigate the incidence or impact of body composition alteration, such as 
sarcopenic obesity, on CV health as these data were not routinely collected by the 
participating centers. Finally, while the patients in this cohort are representative of those 
transplanted for hematologic malignancy, the results cannot be extrapolated to those 
transplanted for other indications. Future study of the CV late effects in survivors of 
transplant for non-malignant conditions is needed.
In summary, this is the largest study of CV late effects in survivors of childhood allogeneic 
HCT to date. We have shown that while the primary outcomes of interest were infrequently 
reported, related late effects and CV risk factors are common in survivors of HCT for 
childhood hematologic malignancy. The cumulative incidence of these events is expected to 
increase as the cohort ages. Prospective, long-term studies are needed to further elucidate the 
roles of genetics, lifestyle, and the transplant process in the development of cardiotoxicity, 
along with testing interventions to decrease the high incidence of cardiac risk factors 
described in this study.
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Figure 1. 
Study population schema
* Includes subjects who did not consent to CIBMTR research; had missing research data or 
information about diagnosis or outcome at 2 years; subjects who had a second transplant in 
the 2 years after first HCT; data no longer required by CIBMTR, and study forms 
incomplete by study closing date.
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Table 1
Characteristics of the study population
Variable N (%)
Year of transplant
  1995–1999 161 (24)
  2000–2004 229 (35)
  2005–2008 271 (41)
Age at HCT,years (N=661)
  Median, range 8.8 (0.3–20.9)
  0–4 173 (26)
  5–9 200 (30)
  10–14 164 (25)
  15–21 124 (19)
Age at end of study follow-up, years
  Median, range 18.5 (3.0–38.0)
  0–9 73 (11)
  10–19 326 (49)
  20–29 236 (36)
  30–38 26 (4%)
Male/Female 367 (56)/294 (44)
Race
  Caucasian 509 (82)*
  African American 46 (7)*
  Hispanic 40 (6)*
  Asian 25 (4)*
  Other 5 (1)*
  Unknown 36 (5)
Underlying disease
  ALL 326 (49)
  AML 203 (31)
  MDS 65 (10)
  CML 55 (8)
  JMML 12 (2)
Donor
  Matched, related donor 236 (36)
  Matched, unrelated donor 169 (25)
  Mismatched, unrelated donor 236 (36)
  Unknown matching, unrelated donor 20 (3)
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Variable N (%)
Graft type
  Bone marrow 381 (58)
  Peripheral blood stem cells 87 (13)
  Umbilical cord blood 193 (29)
Conditioning regimen
  CY/TBI 453 (83)*
  BU/CY 91 (17)*
  CY/other (not TBI or BU) 3 (<1)*
  Other 114 (17)
GVHD prophylaxis
  CSA + MTX + other 292 (46)*
  CSA + other (not MTX or MMF) 134 (22)*
  FK506 + MTX +/- other 69 (11)*
  T-cell depletion + other 58 (9)*
  CSA + MMF + other 53 (8)*
  Other 23 (4)*
  Unknown 32 (5)
Corticosteroid in GVHD prophylaxis regimen
  Yes 204 (32)*
  No 432 (68)*
  Missing 25 (4)
CY= cyclophosphamide, BU = busulfan, TBI= total body irradiation, CSA= cyclosporine, MTX= methotrexate
*
Percentage reported based on number of subjects with available data, patients with unknown data excluded.
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Table 2
Pretransplant treatment and CV characteristics
Variable N (%)*
PreHCT anthracycline
  Yes 482 (73)
  No 175 (27)
  Unknown 4 (<1)
Median anthracycline dose, mg/m2 (range) 112 (7-634)
PreHCT cranial radiation
  Yes 118 (19)
  No 504 (81)
  Unknown 39 (6)
Median cranial radiation dose, cGy (range) 1200 (12-5040)
PreHCT chest radiation
  Yes 86 (14)
  No 540 (86)
  Unknown 35 (5)
Median chest radiation dose, cGy (range) 700 (10-5040)
Hypertension
  Yes 25 (4)
  No 576 (96)
  Unknown 60 (9)
Diabetes or hyperglycemia
  Yes 14 (2)
  No 604 (98)
  Unknown 43 (7)
Triglycerides >150 mg/dl
  Yes 91 (24)
  No 292 (76)
  Missing 278 (42)
HDL cholesterol <40 mg/dl
  Yes 4 (3)
  No 151 (97)
  Missing 506 (77)
LDL cholesterol >130 mg/dl
  Yes 3 (2)
  No 151 (98)
  Missing 507 (77)
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Variable N (%)*
Cardiomyopathy
  Yes 10 (2)
  No 629 (98)
  Not assessed 22 (3)
Cardiac structural defect at diagnosis
  Yes 29 (4)
  No 628 (96)
  Missing 4 (<1)
CAD/myocardial infarction
  Yes 1 (<1)
  No 632 (99)
  Missing 28 (4)
HDL= high-density lipoprotein, LDL= low-density lipoprotein, CAD= coronary artery disease
*
Percentages reported for the categories “unknown” and “missing” reflect the entire population, n=661. The percentages reported for all other 
variables are based on the available data and excludes the number of subjects with missing data.
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Table 3
Cardiovascular and metabolic events.
Variable N (%)δ
CAD/MI 1 (0.2)
Stroke/CVA 4 (0.6)
Cardiomyopathy 22 (3)
Cardiac-related death 3 (0.5)
Multiple events*
  Cardiomyopathy + cardiac-related death 1 (0.2)
  Cardiomyopathy + stroke/CVA 1 (0.2)
Dyslipidemiaφ
  Yes 98 (18)
  No 453 (82)
  Unknown 110 (17)
Triglyceride >150 mg/dl
  Yes 72 (14)
  No 425 (86)
  Unknown 164 (25)
HDL cholesterol <40 mg/dl
  Yes 98 (30)
  No 231 (70)
  Unknown 332 (50)
LDL cholesterol >130 mg/dl
  Yes 63 (20)
  No 253 (80)
  Unknown 345 (52)
Diabetes or hyperglycemia
  Yes 47 (8)
  No 560 (92)
  Unknown 54 (8)
CAD= coronary artery disease; MI= myocardial infarction; CVA= cerebrovascular accident
*
The individual events included in the category multiple events were counted separately in the rows above (e.g. 22 total patients had 
cardiomyopathy; 20 had only cardiomyopathy, 2 had cardiomyopathy and another event)
φ
Dyslipidemia defined as a triglyceride level >150 mg/dl, HDL cholesterol level <40 mg/dl, and/or LDL cholesterol level >130 mg/dl.
δ
Percentages reported for the category “unknown” reflect the entire population, n=661. The percentages reported for all other variables are based 
on the available data and excludes the number of subjects with missing/unknown data.
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Table 4
BMI status at baseline, 2 years post-transplant, and most recent follow-up
Baseline, N (%)φ* Two Years, N (%)φ Most Recent
Follow-up, N (%)φ
Underweight 10 (3) 15 (3) 54 (9)
Normal weight 133 (34) 159 (32) 242 (39)
Overweight 31 (8) 51 (10) 75 (12)
Obese 215 (55) 276 (55) 251 (40)
Missing Data 213 (35) 160 (24) 39 (6)
*59 subjects (9%) were excluded from the baseline assessment due to age less than 2 years.
φ
Percentages reported for the category “Missing Data” reflect the entire population. The percentages reported for all other variables are based on 
the available data and excludes the number of subjects with missing data.
Bone Marrow Transplant. Author manuscript; available in PMC 2018 September 27.
